FDA's Compounding Ban: Your 6-Step Action Plan Before Supply Runs Out

If you're one of the estimated millions of people getting semaglutide or tirzepatide from a compounding pharmacy instead of a brand-name pen, the FDA just put your supply on notice. A proposed rule would end bulk compounding of these drugs -- and if it goes through, it could reshape who gets access, what they pay, and how fast they need to move.

This isn't a done deal yet. But waiting until the rule is final to make a plan is the mistake most people are about to make. Here's exactly what to do right now, in order.

Important: I'm not a doctor. Everything below is based on personal research and published reporting on FDA policy -- not medical advice. Talk to your physician or pharmacist before changing anything about your current prescription.

The Bottom Line

• The FDA is proposing to stop pharmacies from mass-producing ("bulk compounding") semaglutide and tirzepatide, which is different from banning all compounding outright.
• Patient-specific compounding -- where a pharmacy makes your dose for you personally, based on a documented medical need -- is likely to survive even if the bulk rule passes.
• If you're on a compounded GLP-1, the single most useful thing you can do this month is get a written, documented reason from your provider for why you need a compounded version (dose, allergy, formulation) instead of the brand.
• Brand-name prices may not drop right away, but manufacturer savings programs are worth checking now, before you're forced to switch under time pressure.
• Do not panic-buy from unregulated overseas sellers -- that's the mistake that gets people hurt, not the rule itself.

Wait, What Is the FDA Actually Proposing?

Let's clear up the confusion first, because most headlines are flattening a complicated rule into "FDA bans compounded Ozempic."

Compounding pharmacies have been legally allowed to make versions of semaglutide and tirzepatide mainly because both drugs spent long stretches on the FDA's official drug shortage list. Under FDA rules, pharmacies can compound a drug that's normally protected by patent and manufacturing exclusivity if that drug is in short supply. Once the shortage clears, that legal justification is supposed to disappear too.

The catch is that "bulk compounding" -- pharmacies and outsourcing facilities making large batches ahead of time, not for one specific patient -- is a bigger target than one-off, patient-specific compounding. The proposed rule is aimed at that bulk production model, which is also the model that made compounded GLP-1s cheap and widely available over the last two years.

This matters because it changes who gets caught in the crossfire. A person getting a fully custom dose from a small local pharmacy because they need a formulation their doctor documented as medically necessary is in a different legal category than a large-scale outsourcing facility shipping thousands of vials a month. The rule is targeting the second group -- but the ripple effects will hit the first group's wallets too, since a lot of the affordable supply chain runs through those bulk producers.

The 6-Step Protocol: What to Do Before This Finalizes

This is the part that actually matters. Rules like this don't flip a switch overnight -- there's a public comment period, a review process, and typically a transition window. That window is your opportunity.

Step 1: Get your prescription and documentation locked in now

If you're on a compounded semaglutide or tirzepatide dose, ask your prescriber to document why, not just that you need it. "Patient requires 2.5mg dose not available in commercial pens" or "documented allergy to inactive ingredient in brand formulation" is the kind of language that keeps a prescription in the patient-specific compounding lane, which is far less likely to be affected even if the bulk rule passes.

Do this at your next visit, not after the rule is finalized. Once compounding pharmacies are scrambling to sort legitimate patient-specific orders from bulk stock, you don't want to be starting that paperwork from zero.

Step 2: Ask your pharmacy which category they operate under

There are two very different setups here, and most patients have no idea which one they're using:

• 503A pharmacies compound based on an individual prescription for a specific patient. This is the category most likely to survive a bulk compounding rule.
• 503B outsourcing facilities produce in bulk, often without a patient's name on the batch until it ships. This is the category the proposed rule is aimed at.

Call your pharmacy and ask directly: "Are you compounding this specifically for me, or am I getting product from a bulk outsourcing facility?" If you don't get a clear answer, that's useful information too.

Step 3: Price out the brand-name alternative before you need it

Do this even if you never plan to switch. Check current cash prices and manufacturer savings programs for Zepbound (Eli Lilly) and Wegovy/Ozempic (Novo Nordisk). Both companies have run direct-to-consumer discount programs at various points, and pricing shifts fast in this market. If you already have a Step 3 baseline, switching under pressure later is a decision, not a scramble.

If cost is the deciding factor for you between brand and compounded, our breakdown on compounded vs. brand-name semaglutide and tirzepatide walks through the actual price gap as of now.

Step 4: Do not stockpile without medical guidance

I want to be blunt here because this is where people get themselves into trouble. Panic-buying a 6-month supply from an unregulated overseas seller because you're scared of a rule change is a worse risk than the rule itself. Quality control on gray-market peptide sources is inconsistent at best, and there's no guarantee what's actually in the vial.

If your doctor agrees a modest buffer supply makes sense given your titration schedule, that's a medical decision made with oversight. A DIY stockpile from a website you found through an ad is not the same thing.

Step 5: Identify your backup plan before you need one

Ask your provider: "If my specific compounded dose becomes unavailable, what's my next step?" Options typically include switching to the closest available brand-name dose, adjusting your titration schedule, or in some cases switching between semaglutide and tirzepatide entirely.

That last option is a bigger decision than it sounds, since the two drugs work differently and dosing isn't a simple swap. If that's on your radar, read our guide to switching from semaglutide to tirzepatide before you need to make that call under time pressure.

Step 6: Track the public comment period, not just the headlines

FDA rules like this go through a formal comment period before they're finalized, and the timeline can stretch for months. The gap between "FDA proposes" and "FDA finalizes" is exactly where most of the confusion and misinformation lives. Set a calendar reminder to check in every few weeks rather than reacting to every news cycle -- and if you want the full policy history that got us here, our piece on FDA peptide regulations in 2026 tracks it in more depth.

Why This Keeps Happening: The Shortage-to-Ban Cycle

Here's the pattern worth understanding, because it's not new and it's not likely to be the last time it happens.

Semaglutide and tirzepatide both spent extended periods on the FDA's shortage list as demand outpaced manufacturing. During that window, compounding filled a real gap -- people who couldn't get a brand-name pen could still get treatment. Once the shortage officially ended, the legal basis for a lot of that compounding went with it, and compounders have been fighting to keep operating in that gray zone ever since.

This tension -- manufacturers wanting exclusivity protected, compounders arguing patients still can't afford or access brand product, and regulators trying to draw a legal line -- is the same fight playing out across other peptide categories too. If you want the bigger-picture version of this fight, including how it's playing out for other peptides like BPC-157, see our coverage of the grey-market peptide supply collapse.

The billion-dollar problem underneath all of this is straightforward: brand-name GLP-1s remain expensive for a huge share of patients, insurance coverage is inconsistent, and every rule that tightens compounding access shifts more people back toward a price point many can't sustain. That access gap is exactly why the comment period on this proposal matters -- it's the mechanism through which patients, doctors, and pharmacies can flag real-world impact before the rule locks in.

What Happens If You're Mid-Titration When the Rule Changes

This is the scenario I'd worry about most if I were reading this as a current compounded-GLP-1 patient: you're partway through dose escalation, and your specific dose disappears with no warning.

Stopping a GLP-1 abruptly, or having to restart at a lower dose because your exact strength isn't available, isn't just inconvenient -- it can trigger the rebound effects that show up when these drugs are interrupted. If you want to understand what that actually looks like physically, read our breakdown of metabolic rebound and weight cycling after GLP-1 withdrawal before you're in that situation, not during it.

The fix isn't complicated: have the brand-name equivalent dose identified in advance (Step 3 above), and have your provider ready to write that prescription the moment it's needed. A short gap of a week or two, planned for, is manageable. An unplanned gap during active titration is what causes the roughest reactions.

FAQ

Will compounded semaglutide and tirzepatide become illegal overnight? No. Rules like this go through a public comment period and typically include a transition window before enforcement begins. There's no version of this where compounding stops nationwide the day the proposal is announced.

What's the real difference between 503A and 503B compounding? 503A pharmacies compound a specific formulation for a named patient based on an individual prescription. 503B outsourcing facilities produce larger batches, often without one patient's name attached until distribution. The proposed rule is targeting the bulk (503B-style) model, not necessarily individualized patient-specific compounding.

Will this make brand-name Ozempic, Wegovy, or Zepbound cheaper? Not automatically. Reduced competition from compounded versions could theoretically ease supply pressure on manufacturers, but pricing decisions are separate from supply decisions. Don't count on a price drop as your Plan A.

Can I still get a compounded GLP-1 if I have a documented medical reason? Patient-specific compounding for a documented medical need -- a dose not commercially available, or a formulation issue like an allergy -- is generally treated differently under FDA rules than bulk production. This is exactly why Step 1 above (getting that documentation now) matters.

What should I do if my current compounded dose becomes unavailable? Talk to your provider about the closest available brand-name dose and whether your titration schedule needs adjusting. Don't source a replacement from an unregulated seller, the quality risk is not worth the convenience.

Next Step

If you're currently on a compounded semaglutide or tirzepatide dose, the action item today is simple: call your prescriber's office and ask them to document the specific medical reason for your compounded formulation in your chart. That single step does more to protect your access than anything else on this list, and it costs you nothing but a phone call.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research, not medical recommendations.

Sources

1. The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors, Cell Metabolism, 2026
2. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis, Medicine, 2026
3. Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials, Diabetes, Obesity & Metabolism, 2026
4. Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular-Kidney-Metabolic Syndrome, Diabetes, Obesity & Metabolism, 2026